A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

• Status: Recruiting
• Trial end date: 2025-12-31

Summary

This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd